文献速递甲状腺疾病

高通量筛选鉴定未分化甲状腺癌有效系统治疗药物

A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

多西他赛、LBH-589和普拉曲沙经体外及原位/PDX模型验证,LBH-589在所有模型中均显示显著肿瘤生长抑制。结论提示高通量筛选可发现对侵袭性甲状腺癌(尤其TP53突变者)优先有效的药物类别。

要点

  • LBH-589在所有测试模型中均显著抑制肿瘤生长。
  • 多西他赛仅在TP53突变背景下显示显著肿瘤生长抑制。

核心结论

  • 高通量筛选鉴定出对侵袭性甲状腺癌优先有效的系统治疗药物类别,尤其针对TP53突变者。
  • 原位和PDX模型中的临床前验证可支持在非BRAF突变或BRAF/MEK抑制剂耐药ATC中启动早期临床试验。

研究设计与样本

  • 采用细胞增殖、集落形成、原位甲状腺模型和患者来源异种移植(PDX)模型验证所选药物。

主要发现

  • LBH-589在所有测试治疗模型中均检测到显著肿瘤生长抑制(TGI)。
  • 普拉曲沙在原位乳头状甲状腺癌模型和2个PDX模型中显示显著TGI。
  • 多西他赛仅在TP53突变背景下显示显著TGI。

临床怎么用

  • 对于非BRAF突变或对BRAF/MEK抑制剂耐药的ATC患者,高通量筛选出的药物类别(如LBH-589、普拉曲沙)可考虑作为早期临床试验的候选。
  • TP53突变状态可能提示多西他赛的潜在获益人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the use of aggressive multimodality treatment, most anaplastic thyroid carcinoma (ATC) patients die within a year of diagnosis. Although the combination of BRAF and MEK inhibitors has recently been approved for use in BRAF-mutated ATC, they remain effective in a minority of patients who are likely to develop drug resistance. There remains a critical clinical need for effective systemic agents for ATC with a reasonable toxicity profile to allow for rapid translational development. MATERIAL AND METHODS: Twelve human thyroid cancer cell lines with comprehensive genomic characterization were used in a high-throughput screening (HTS) of 257 compounds to select agents with maximal growth inhibition. Cell proliferation, colony formation, orthotopic thyroid models, and patient-derived xenograft (PDX) models were used to validate the selected agents. RESULTS: Seventeen compounds were effective, and docetaxel, LBH-589, and pralatrexate were selected for additional in vitro and in vivo analysis as they have been previously approved by the US Food and Drug Administration for other cancers. Significant tumor growth inhibition (TGI) was detected in all tested models treated with LBH-589; pralatrexate demonstrated significant TGI in the orthotopic papillary thyroid carcinoma model and 2 PDX models; and docetaxel demonstrated significant TGI only in the context of mutant TP53. CONCLUSIONS: HTS identified classes of systemic agents that demonstrate preferential effectiveness against aggressive thyroid cancers, particularly those with mutant TP53. Preclinical validation in both orthotopic and PDX models, which are accurate in vivo models mimicking tumor microenvironment, may support initiation of early-phase clinical trials in non-BRAF mutated or refractory to BRAF/MEK inhibition ATC.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Henderson YC, Mohamed ASR, Maniakas A, et al. A High-throughput Approach to Identify Effective Systemic Agents for the Treatment of Anaplastic Thyroid Carcinoma. J Clin Endocrinol Metab. 2021. PMID: 34120183. doi:10.1210/clinem/dgab424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。